An Investigation of the Effect of NNC0662-0419 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) and Gastric Emptying in Women of Non-childbearing Potential With Overweight or Obesity
Novo Nordisk A/S
Summary
The purpose of this clinical study is to find out if NNC0662-0419 is safe and effective to be taken together with other medicines, like birth control pills, and emptying of the stomach in women not able to become pregnant living with overweight or obesity. There are 3 study treatments in this study, participants will get all of the treatments, NNC0662-0419 the treatment being tested, Altavera a type of birth control pill, Acetaminophen a common type of mild painkiller.
Eligibility
- Age range
- 18–64 years
- Sex
- Female
- Healthy volunteers
- Yes
Inclusion Criteria: * Female (sex assigned at birth) of non-childbearing potential. * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Body weight more than or equal to (≥) 60.0 kilogram (kg). * Considered to be generally healthy, except for overweight or obesity, based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related produc…
Interventions
- DrugNNC0662-0419
Once-weekly subcutaneous NNC0662-0419 will be administered using a pen injector
- DrugOral contraceptive
An oral contraceptive Altavera \[levonorgestrel (LN) 0.15 milligram (mg) and ethinyl estradiol (EE) 0.03 mg\] will be administered orally.
- DrugAcetaminophen
A single dose of acetaminophen will be administered orally.
Location
- Altasciences Clinical Kansas, Inc.Overland Park, Kansas